reason report
weigh genesight
bottom line report revenue line
us street larg remain flat
quarter genesight continu face headwind
coverag announc larg employ howev
antm/op evicor reiter non-coverag decis
genesight remain key driver long-term outlook
challeng growth believ investor like wait
longer look sign potenti upsid busi
statu unh/op reach mileston test
remain market perform pt move
mute long-term reimburs outlook
genesight volum uptak solid broader uptak conting
major commerci payer adopt current lack despit
volum growth posit coverag decis genesight
continu face headwind reiter non-coverag decis
evicor genesight need broader commerci payer
coverag drive deeper penetr adopt across market
impact lab benefit manag program remain
chang expect quarter recal genesight
experienc revenu adjust last quarter actual cash
collect fell behind industry-wid laboratori benefit manag
lbm scrutin payment genesight outlook remain murki
signific number compet product though support
limit data market management share full data set payer
updat us expect commerci reimburs
area investor manag reiter remain track
reach accret later year backdrop
season weak quarter counysl reach posit oper incom
ahead schedul recal ltm sale counsyl prenat
busi acquisit help diversifi away core hereditari
cancer test manag believ see benefit
sale forc cross-train land around rep think
right size sale team
guid estim chang tighten guid
revenue ep vs con issu new
guid revenue ep vs con
lower rev slightli
slightli rais ep estim
rev vs prior ep vs base
slower growth increas profit
net debt total capit
life scienc tool diagnost
blend dcf price-to-earnings
year price history/av daili volume mil
compani inform svb leerink llc research
revenu mm oper ep present includ effect stock option expens reflect adjust per recent file
pleas refer page import disclosur price chart analyst certif
continu stori transform hereditari cancer test leader
revenu compani that diversifi test portfolio recent
year acquir bolt-on compani offer test special area relat
hereditari test despit view hereditari test remain declin busi
price pressur strengthen test base recent acquisit counsyl
reproduct test prior acquisit assurex health
pharmacogenom test given loss patent protect posit brca
test hc test busi expect see heat competit
smaller entrant op genedx ambri genet larger refer lab
lh competit price unfold competitor becom even agil
pama protect access medicar act medicar price pressur expect
price remain pressur longer term hc test done good job
reimburs year success mitig price risk
nevertheless believ competitor lower continu drive penetr
market take market share lower cost genet test becom widespread
loss patent brca gene test longer protect posit
ovarian breast cancer test expect test revenu continu declin
gradual despit slight volum growth still market share brca test
market base revenu entrant provid genet test lower cost
believ mygn market share begin erod privat payer renegoti lower
contract rate expect genet test industri grow rate y/i certain
diseas test etc grow greater
light headwind undergo transform phase compani
diversifi test portfolio recent year acquir bolt-on compani offer
test special area relat hc howev see challeng new
product portfolio gain traction coverag without adequ commerci coverag
attempt obtain broader commerci reimburs genesight product
remain largest contributor upsid view reimburs per test
remain uncertain econom payer studi publish remain market perform
await public data improv reimburs
trade price-to-earnings believ blend dcf analysi price-to-earnings
appropri given growth potenti test legaci hereditari cancer
busi use blend averag discount price-to-earnings peer
average dcf analysi valu reach price target dcf includ
long-term growth equiti risk premium beta
could get broader adopt among commerci payer result aggress
negoti contract could lead signific upsid revenu gener
success negoti hc test contract given well-entrench posit
commun oncologist could potenti replic market well
inclus test nccn uspstf other could benefit test futur
drive signific payer adopt improv coverag test repres upsid risk
estim recommend medic societi includ american colleg
neuropsychiatri potenti drive chang guidelin could lead improv
coverag revenu upsid genesight
qualiti control problem among test competitor could drive volum
problem recent highlight despit impact limit believ
qualiti control issu competitor could drive provid use
establish hc test clinvar databas qualiti improv time would
embolden variant databas even believ
fda could regul ldt lab develop test increas pressur smaller lab
resourc believ like fare better vs competit chang
consolid within industri also mean could target given patient
databas wealth proprietari inform collect year could
view databas person medicin inform patient recruit
companion diagnost could growth driver sector longer term still lever
believ could present upsid portfolio test evolv biomark requir
therapi select therapi manag
dollar thousand except per share data
good sold
net incom non-control interest
sg sale
 sale
oper expens sale
pharma clinic servic
 revenu segment
pharma clinic servic
compani file svb leerink estim
exclud research revenu histor period
